Physician profile
Antonio Tan
NPI 1134277569
$15,253.22
in general payments reported to CMS, 2019-2025
54 companies · $2,294 in 2025
The $2,294 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,378 · 2020: $2,085 · 2021: $2,082 · 2022: $2,122 · 2023: $2,621 · 2024: $1,671 · 2025: $2,294.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,802 · Travel and Lodging: $784.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,801.77 |
| Travel and Lodging | $784.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,401.50 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $1,436.26 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,054.86 | 2019-2025 | Jardiance |
| Abbott Laboratories | $1,003.43 | 2022-2025 | Freestyle Libre 3 |
| Abbvie INC. | $960.95 | 2019-2024 | Ubrelvy, Linzess, Viberzi |
| Stryker Corporation | $784.24 | 2025 | Na |
| Amarin Pharma, INC. | $582.34 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $573.47 | 2019-2025 | Verquvo, Belsomra, Steglatro |
| Lilly USA, LLC | $534.32 | 2019-2025 | Jardiance, Zepbound, Emgality |
| Glaxosmithkline, LLC. | $534.08 | 2019-2025 | Arexvy, Trelegy Ellipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $530.21 | 2019-2025 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $488.31 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $464.38 | 2021-2025 | |
| Amgen INC. | $388.69 | 2019-2025 | Repatha, Krystexxa, Tepezza |
| Esperion Therapeutics, INC. | $387.84 | 2020-2025 | Nexletol |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Antonio Tan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.